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It is known that tumors resistant to anticancer prepa­
rations in the majority of cases demonstrate marked 
aggressiveness and ability to quick progression. 
Combination of chemoresistance with the resistance 
to radio­ and phototherapy additionally complicates 
the treatment of the patients with chemoresistant tu­
mors [1]. The problem of therapy of the patients with 
chemoresistant tumors requires not only improvement 
of the therapy with already existing preparations and 
the development of new ones, but also the search for 
new approaches for treatment of such patients.
In our earlier studies we have shown that the cells 
and explants of human chemoresistant tumors (soft 
tissue tumors of locomotor system, and epithelial 
tumors of female reproductive system) and animal 
tumors (В16 melanoma and transplantable MC­
rhabdomyosarcoma) demonstrate elevated sensi­
tivity to the action of LAK [2, 3]. This fact has been 
proved not only in the study in vitro, but also upon 
immunotherapy of mice bearing doxorubicin­resistant 
MC­rhabdomyosarcoma [4]. To study the sensitivity of 
explants of human tumors, we have used the method 
developed by us for determination of individual sen­
sitivity to preparations widely used for chemotherapy 
(doxorubicin, methotrexate, vincristine, carboplatin, 
cyclophosphan). It is necessary to note that the phe­
nomenon of elevated sensitivity of resistant tumors 
to the action of LAK was observed even if there was 
resistance only to a single preparation [3].
So, the question arises — is it possible to elevate an­
titumor action of LAK against chemoresistant tumors? 
As one approach, we have used doxorubicin (Dox) at 
the low doses — according to the data of literature, this 
drug and a number of other chemopreparations pos­
sess immunomodulating effect at the low doses. 
For example, low doses Dox may promote functions 
of the cells of immune system, in particular peritoneal 
exudate (macrophages, neutrophils, lymphocytes) 
and elevate production of INFγ, TNFα [5, 6]. The use 
of low (subtoxic) doses of chemopreparations returns 
to lymphocytes the ability for cytotoxic action toward 
chemoresistant renal and prostate tumors that is reali­
zed via perforin­dependent and perforin­independent 
mechanisms [7]. The authors concluded that the use 
of the low doses of chemopreparations results in “sen­
sibilization” of chemoresistant tumors. 
Dox at the low doses may promote effect of TNFα, 
as it was shown in the experiments with EL4­resistant 
murine lymphoma cells. Antitumor activity of cytotoxic 
splenocytes and thymocytes increased, and such in­
crease correlated with elevated survival of mice. The 
effect was observed also for spleen macrophages and 
LAK [8]. Doxorubicin possesses ummunomodulatory 
action, and if it is used as a component of co­polymer 
Dox­immunoglobulin, activity of LAK and natural killer 
cells was higher [6].
There are other preparations able to promote tumor 
cell lysis; for example, mitomycin and cysplatin may 
elevate the sensitivity of colon cancer cells of SW480 
line to apoptotic signals [9]. The treatment of human 
ovarian cancer cells of SVO3 line with paclitaxel ele­
vated their sensitivity to LAK­mediated lysis [10].
Unfortunately, the number of studies aimed on 
evaluation of antitumor activity of LAK against resistant 
tumor cells using low doses of Dox or other antican­
cer preparations is limited. That’s why the present 
research was directed on the development of optimal 
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conditions for elevation of antitumor activity of LAK 
against Dox­resistant tumors.
maTerials and meThods
In the study, BALB/c and C57BL/6 mice weighting 
15–20 g bred in the vivarium of R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobiolo­
gy, NAS of Ukraine (Kyiv, Ukraine) were used. As ex­
perimental tumor models, we have used the strains 
generated by us: 1) В16 melanoma and transplantable 
MC­rhabdomyosarcoma cells resistant to Dox; 2) В16 
melanoma and transplantable MC­rhabdomyosar­
coma cells sensitive to Dox.
The studies were performed on tumor explants 
and isolated tumor cells and lymphocytes from lymph 
nodes of experimental animals.
Lymphokine­activated cells (LAK) were obtained 
by incubation of lymphocytes of lymph nodes of tumor 
bearing mice with recombinant IL­2 (3 x 106 cells with 
1000 МU RIL­2) for 2 h at 37 °С.
Lymphocytes and LAK were treated with 0.4 µg/ml 
doxorubicin (Ebeve, Austria) for 24 h in complete 
RPMI­1640 medium at 37 °С. The optimal dose and 
conditions of cultivation were estimated prior to 
experiments (calibration of preparation dose at the 
base of therapeutic one accounting animals weight, 
has been done).
The following systems of cultivation in diffusion 
chambers were used: 1) cultivation of lymphocytes, 
Dox­pretreated, with tumor cells or explants; 2) cul­
tivation of LAK, Dox­pretreated, with tumor cells or 
explants; 3) cultivation of tumor cells or lymphocytes 
after combined treatment with Dox and IL­2. Controls 
were as follow: 1) tumor growth at standard condi­
tions; 2) the growth of tumor cells with non­activated 
lymphocytes; 3) the growth of tumor cells with LAK. 
Evaluation of antitumor action of lymphocytes was 
performed at the base of tumor growth morphology 
[05]. All experiments were done with the use of the cells 
and explants of both Dox­sensitive and Dox­resistant 
MC­rhabdomyosarcoma and B16 melanoma.
resulTs and discussion
The study of anticancer activity of LAK received 
from lymphocytes from lymph nodes of mice was car­
ried out in the dynamics of tumor growth (at the days 7 
and 14 after tumor transplantation). At the day 7, tumor 
explants were studied because it was impossible to 
receive required quantity of tumor cells (at this period 
tumors were too small (0.06–0.09 g)), and at the day 14 
isolated tumor cells and explants were examined.
At the day 7 after tumor transplantation, the com­
parative study of antitumor action of non­activated 
lymphocytes and LAK from animals bearing transplant­
able MC­rhabdomyosarcoma resistant and sensitive 
to Dox upon the influence of low doses of the drug has 
shown the following: upon cultivation of lymphocytes 
from mice bearing resistant MC­rhabdomyosarcoma 
it has been shown that pretreatment of non­activated 
lymphocytes with Dox elevated their cytotoxicity to 
the level of LAK; pretreatment of LAK with Dox did not 
alter their antitumor action. Lymphocytes cultivated 
with IL­2 and Dox possess the same antitumor activ­
ity. In the case of sensitive tumor, pretreatment of 
lymphocytes with Dox did not alter antitumor action 
of non­activated lymphocytes, but elevated antitumor 
activity of LAK (Fig. 1).
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fig. 1. Antitumor action of lymphocytes of mice bearing trans­
plantable MC­rhabdomyosarcoma resistant and sensitive to 
doxorubicine at day 7 after tumor transplantation. 1 — migration 
of single cells, initial stages of formation of the monolayer; 2 — in­
tense formation of monolayer; 3 — single conglomerates
In analogous way, the study was performed for 
lymphocytes and tumor cells of mice bearing mela­
noma В16 sensitive and resistant to Dox. In the case of 
resistant tumor explants, the highest antitumor activity 
was observed for lymphocytes cultivated with IL­2 and 
Dox. However, pretreatment with Dox did not alter cy­
totoxic activity of lymphocytes and LAK (which activity 
was higher than that of lymphocytes). In the case of 
sensitive tumor explants, pretreatment of lymphocytes 
with Dox led to elevation of their cytotoxic activity to 
the level of that of LAK; the influence of pretreatment 
of LAK with Dox or its combination with IL­2 was not 
observed (Fig. 2).
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fig. 2. Antitumor action of lymphocytes of mice bearing 
melanoma B16 resistant and sensitive to doxorubicine at day 7 
after tumor transplantation. 1 — migration of single cells, initial 
stages of formation of the monolayer; 2 — intense formation of 
monolayer; 3 — single conglomerates; 4 — intense formation 
of conglomerates
Comparison of the results of antitumor activity of 
activated and non­activated lymphocytes received at 
different conditions against the explants of the resis­
tant В16 melanoma and transplantable MC­rhabdo­
myosarcoma revealed some differences; in particular, 
the pretreatment of non­activated lymphocytes with 
Dox at low doses elevated their antitumor activity upon 
cultivation with MC­rhabdomyosarcoma explants, but 
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not in the case of melanoma cells. The highest antitu­
mor activity against melanoma cells was observed for 
lymphocytes incubated with IL­2 and Dox. It is neces­
sary to note that in the case of MC­rhabdomyosarcoma 
cells, antitumor activity of lymphocytes elevated after 
using all variants of pretreatment (see Fig. 1, 2).
At the day 14 after tumor transplantation, in the 
case of resistant MC­rhabdomyosarcoma the highest 
antitumor action was registered for LAK obtained from 
lymphocytes pretreated with Dox. The pretreatment 
with Dox did not influence the activity of non­activated 
lymphocytes; cultivation of lymphocytes with IL­2 and 
Dox also did not elevate their antitumor action (Fig. 3). 
For resistant melanoma B16 cells, the highest activity 
was registered for LAK obtained from lymphocytes 
pretreated with Dox; Dox­pretreatment of non­ac­
tivated lymphocytes also elevated their antitumor 
potency. Similarly to MC­rhabdomyosarcoma model, 
combined treatment did not influence antitumor action 
of lymphocytes (Fig. 4).
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fig. 3. Antitumor action of lymphocytes of mice bearing trans­
plantable MC­rhabdomyosarcoma resistant and sensitive to 
doxorubicine at day 14 after tumor transplantation. 1 — migration 
of single cells, initial stages of formation of the monolayer; 2 — in­
tense formation of monolayer; 3 — single conglomerates
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fig. 4. Antitumor action of lymphocytes of mice bearing melano­
ma В16 resistant to doxorubicine at day 14 after tumor transplan­
tation. 1 — migration of single cells, initial stages of formation of 
the monolayer; 2 — intense formation of monolayer; 3 — single 
conglomerates; 4 — intense formation of conglomerates
The common pattern of lymphocytes from mice 
bearing sensitive MC­rhabdomyosarcoma and В16 
melanoma was the absence of influence of Dox­pre­
treatment on their antitumor activity.
As it was mentioned above, the task of present re­
search was the development of approach for elevation 
of antitumor activity of LAK against chemoresistant 
tumors (MC­rhabdomyosarcoma, В16 melanoma) 
using low doses of Dox. The use of different systems 
for cultivation of lymphocytes from mice bearing Dox­
sensitive and Dox­resistant tumors allowed to show 
that, firstly, the conditions for elevation of activity of 
LAK against Dox­resistant tumors differ from these 
for Dox­sensitive mice; secondly, the influence of low 
doses of Dox on antitumor activity of lymphocytes from 
mice with Dox­resistant MC­rhabdomyosarcoma and 
В16 melanoma is also different, especially at early 
stages of tumor growth.
Such effect of Dox one could explain by its ability 
for imunomodulating action. It is known that the total 
population of LAK is heterogeneous and is presented 
by different subpopulations of killer cells [11]. Accord­
ing to the data of literature, Dox may elevate the activity 
of different cells of immune system. In particular, the 
data showing that upon the development of resistance 
to adriamycin, increased expression of I class antigens 
of histocompatibility complex (А, B, C) in ovarian 
cancer cells promoting their lysis, point on the pos­
sibility of activation of cytotoxic T­lymphocytes [12]. 
The influence of adriamycin is not limited by cytotoxic 
T­lymphocytes, but involves also natural killer cells 
and LAK; this fact has been shown upon the study of 
bladder cancer cells, lymphocytes of peripheral blood 
and lymphocytes infiltrating tumor [13]. The authors 
consider that the treatment of tumor cells with low 
doses of adrsamycin induces their elevated sensitivity 
to the action of different killer cells. The similar point 
of view has been documented in another study where 
elevated expression of ICAM­1 in ovarian cancer cells 
resistant to packlitaxel considered as a main cause 
of elevated sensitivity of the cells to LAK action, has 
been reported  [10]. The data on positive influence of 
low dose Dox on Dox­resistant tumor cells are in ac­
cordance with our earlier results for in vivo and in vitro 
studies that showed that simultaneous introduction of 
Dox and LAK to mice bearing Dox­resistant MC­rhab­
domyosarcoma promoted the effect of LAK [2].
In summary, one may conclude that the effect of 
low dose Dox is a result of both elevated activity of 
different killer cells and increased sensitivity of the 
tumor to their action. The presented data are sup­
porting the reported earlier results and show that low 
dose Dox may be used for treatment of tumor cells and 
for generation of LAK possessing higher activity, and 
these effects are complementary. That’s why one may 
consider that the low doses of anticancer drugs may be 
used in regular chemotherapy, and immunomodulating 
effect of Dox will not be suppressed [14].
The results of the present study have shown that for 
elevation of antitumor activity of LAK toward Dox­resis­
tant MC­rhabdomyosarcoma and В16 melanoma cells, 
low dose Dox could be used upon special conditions 
of LAK generation. These data make reasonable the 
further study of the processes responsible for elevated 
sensitivity of resistant tumor cells to cytotoxic action 
of lymphocytes and of optimizing effect of low dose 
Dox; the research of  expression of surface molecules 
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on lymphocytes and resistant tumor cells will be es­
pecially important.
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ИспользоВанИе малых доз доксорубИцИна 
для усИленИя актИВностИ лак В отношенИИ 
эксплантатоВ И опухолеВых клеток 
мх-рабдомИосаркомы И меланомы В16, резИстентных 
к доксорубИцИну
Цель: изучить влияние малых доз доксорубицина на противоопухолевое действие активированных (ЛАК) и неактивированных 
лимфоцитов лимфатических узлов по отношению к опухолевым клеткам мышей с резистентными и чувствительными к 
доксорубицину перевивной МХ-рабдомиосаркомой и меланомой В16. Материалы и методы: исследования проведены на 
мышах линии BALB/c с МХ-рабдомиосаркомой и С57BL/6 c меланомой В16. Эксплантаты, опухолевые клетки и лимфоциты 
культивировали в диффузионных камерах и окраской фильтров гематоксилином по Караччи. Исследовали морфологическую 
картину полученных препаратов с учетом критериев роста опухоли. Результаты: сопоставление результатов противоопухолевой 
активности активированных и неактивированных лимфоцитов, полученных в различных условиях, показало следующее. 
На 7-е сутки у мышей з резистентной МХ-рабдомиосаркомой наибольшей противоопухолевой активностью обладали 
неактивированные лимфоциты, предварительно обработанные малыми дозами докорубицина, а у мышей з резистентной 
меланомой В16 — лимфоциты после сочетанного культивирования с ИЛ-2 и доксорубицином. На 14-е сутки роста опухоли 
наибольшей цитотоксической активностью обладали ЛАК, полученные из лимфоцитов, предварительно обработанных 
доксорубицином, в отношении резистентных опухолевых клеток как перевивной МХ-рабдомиосаркомы, так и меланомы В16. 
Относительно чувствительных клеток указанных опухолей такой эффект не отмечался. Выводы: для усиления противоопухолевой 
активности ЛАК по отношению к клеткам МХ-рабдомиосаркомы и меланомы В16, резистентных к доксорубицину, могут быть 
использованы малые дозы доксорубицина при соблюдении определенных условий получения ЛАК. 
Ключевые слова: перевивная МХ-рабдомиосаркома, меланома В16, резистентность, доксорубицин, ЛАК.
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